HRP20010484B1 - Supstituirani benzimidazoli, njihovo pripravljanje i korištenje - Google Patents

Supstituirani benzimidazoli, njihovo pripravljanje i korištenje

Info

Publication number
HRP20010484B1
HRP20010484B1 HR20010484A HRP20010484A HRP20010484B1 HR P20010484 B1 HRP20010484 B1 HR P20010484B1 HR 20010484 A HR20010484 A HR 20010484A HR P20010484 A HRP20010484 A HR P20010484A HR P20010484 B1 HRP20010484 B1 HR P20010484B1
Authority
HR
Croatia
Prior art keywords
alkyl
phenyl
hydrogen
ring
unbranched
Prior art date
Application number
HR20010484A
Other languages
English (en)
Croatian (hr)
Inventor
Lubisch Wilfried
Kock Michael
Hoeger Thomas
Schult Sabine
Grandel Roland
Mueller Reinhold
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999116460 external-priority patent/DE19916460B4/de
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of HRP20010484A2 publication Critical patent/HRP20010484A2/hr
Publication of HRP20010484B1 publication Critical patent/HRP20010484B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010484A 1998-11-27 1999-11-23 Supstituirani benzimidazoli, njihovo pripravljanje i korištenje HRP20010484B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19854933 1998-11-27
DE1999116460 DE19916460B4 (de) 1999-04-12 1999-04-12 Substituierte Benzimidazole, deren Herstellung und Anwendung
PCT/EP1999/009004 WO2000032579A1 (de) 1998-11-27 1999-11-23 Substituierte benzimidazole und ihre verwendung als parp inhibitoren

Publications (2)

Publication Number Publication Date
HRP20010484A2 HRP20010484A2 (en) 2003-04-30
HRP20010484B1 true HRP20010484B1 (hr) 2010-08-31

Family

ID=26050434

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010484A HRP20010484B1 (hr) 1998-11-27 1999-11-23 Supstituirani benzimidazoli, njihovo pripravljanje i korištenje

Country Status (32)

Country Link
US (2) US6448271B1 (cs)
EP (1) EP1133477B1 (cs)
JP (1) JP3432800B2 (cs)
KR (1) KR100417779B1 (cs)
CN (1) CN1184208C (cs)
AR (1) AR021400A1 (cs)
AT (1) ATE259789T1 (cs)
AU (1) AU764216B2 (cs)
BG (1) BG65047B1 (cs)
BR (1) BR9915701A (cs)
CA (1) CA2352554C (cs)
CZ (1) CZ300148B6 (cs)
DE (1) DE59908600D1 (cs)
DK (1) DK1133477T3 (cs)
ES (1) ES2216625T3 (cs)
HK (1) HK1042084B (cs)
HR (1) HRP20010484B1 (cs)
HU (1) HUP0200749A3 (cs)
IL (2) IL143303A0 (cs)
MY (1) MY128488A (cs)
NO (1) NO20012570L (cs)
NZ (1) NZ511825A (cs)
PL (1) PL196367B1 (cs)
PT (1) PT1133477E (cs)
RU (1) RU2001117757A (cs)
SI (1) SI1133477T1 (cs)
SK (1) SK285529B6 (cs)
TR (1) TR200101498T2 (cs)
TW (1) TWI247741B (cs)
UA (1) UA61158C2 (cs)
WO (1) WO2000032579A1 (cs)
ZA (1) ZA200104118B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
CZ20011546A3 (cs) 1998-11-03 2001-08-15 Basf Aktiengesellschaft Derivát substituovaného 2-fenylbenzimidazolu, způsob jeho přípravy a jeho použití
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
FR2812878B1 (fr) * 2000-08-08 2002-10-11 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
PL365080A1 (en) * 2000-08-08 2004-12-27 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816941B1 (fr) * 2000-11-23 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2002068407A1 (en) * 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
HUP0303460A3 (en) 2001-03-12 2004-07-28 Avanir Pharmaceuticals San Die Benzimidazole compounds for modulating ige and inhibiting cellular proliferation and pharmaceutical compositions containing them
US20040242635A1 (en) * 2001-03-30 2004-12-02 Painter Rachel J. Encapsulated dyes in cosmetic compositions
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2004013333A2 (de) 2002-07-26 2004-02-12 Basf Plant Science Gmbh Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
WO2004035549A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
HU0301154D0 (en) * 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
EP2166099B1 (en) 2005-03-08 2012-12-19 BASF Plant Science GmbH Expression enhancing intron sequences
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
AU2012200399B2 (en) * 2005-04-11 2013-07-11 Abbvie Ireland Unlimited Company 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
BRPI0611814A2 (pt) * 2005-06-10 2008-12-09 Bipar Sciences Inc moduladores parp e tratamento de cÂnceres
US7825543B2 (en) 2005-07-12 2010-11-02 Massachusetts Institute Of Technology Wireless energy transfer
CN101860089B (zh) 2005-07-12 2013-02-06 麻省理工学院 无线非辐射能量传递
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP5227796B2 (ja) 2005-09-29 2013-07-03 アボット・ラボラトリーズ ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
US7462724B2 (en) 2005-11-15 2008-12-09 Abbott Laboratories Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
ME02121B (me) * 2006-01-17 2014-06-30 Abbvie Ireland Unlimited Co Kombinovana terapija sa parp inhibitorima
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
EP2007733B1 (en) * 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
US20070259937A1 (en) * 2006-05-02 2007-11-08 Giranda Vincent L Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
JP2010502731A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
BRPI0809655B8 (pt) 2007-04-13 2021-05-25 Millennium Pharm Inc uso de um composto e um agente terapêutico,composição farmacêutica,e,kit
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US8138168B1 (en) * 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2009049109A1 (en) * 2007-10-12 2009-04-16 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
EP2240466B1 (en) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
JP2011511078A (ja) * 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
CA2782014C (en) 2009-11-27 2021-08-31 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
AU2010325563B2 (en) 2009-11-27 2017-02-02 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
EP2542533B1 (de) * 2010-03-04 2014-09-10 Bayer Intellectual Property GmbH Fluoralkyl-substituierte 2-amidobenzimidazole und deren verwendung zur steigerung der stresstoleranz in pflanzen
EP2709618A4 (en) * 2011-05-10 2014-11-05 UNIVERSITé LAVAL METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
JP5902299B2 (ja) * 2011-07-26 2016-04-13 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐａｒｐ−１阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−インダゾール−４−カルボキサミド誘導体
EP2561759A1 (en) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102617502A (zh) * 2012-03-19 2012-08-01 江苏先声药物研究有限公司 一类苯并噁唑衍生物及其医药应用
BR112015004858A2 (pt) * 2012-09-05 2017-07-04 Bayer Cropscience Ag uso de 2-amidobenzimidazóis, 2-amidobenzoxazóis e 2-amidobenzotiazóis substituídos ou sais dos mesmos como substâncias ativas contra estresse abiótico em plantas
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
CN104230898B (zh) * 2013-06-17 2016-06-29 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN104230897B (zh) * 2013-06-17 2016-07-06 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN103483322A (zh) * 2013-08-21 2014-01-01 中国药科大学 5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018054989A1 (en) * 2016-09-20 2018-03-29 Centre Leon Berard Benzoimidazole derivatives as anticancer agents
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
CN109232540A (zh) * 2018-06-15 2019-01-18 深圳市坤健创新药物研究院 一种取代苯并咪唑衍生物及应用
CN108997320A (zh) * 2018-08-30 2018-12-14 深圳市坤健创新药物研究院 一种含氟取代苯并咪唑衍生物及应用
US20210347758A1 (en) 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004771A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
WO1998033802A1 (en) * 1997-02-01 1998-08-06 Newcastle University Ventures Limited Quinazolinone compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1354554U (cs)
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004771A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
WO1998033802A1 (en) * 1997-02-01 1998-08-06 Newcastle University Ventures Limited Quinazolinone compounds

Also Published As

Publication number Publication date
JP2002531442A (ja) 2002-09-24
HRP20010484A2 (en) 2003-04-30
KR20010080596A (ko) 2001-08-22
TWI247741B (en) 2006-01-21
USRE39608E1 (en) 2007-05-01
CZ20011855A3 (cs) 2001-08-15
EP1133477A1 (de) 2001-09-19
SI1133477T1 (en) 2004-06-30
CA2352554A1 (en) 2000-06-08
AU3034300A (en) 2000-06-19
CN1184208C (zh) 2005-01-12
BG105596A (en) 2002-02-28
BR9915701A (pt) 2001-08-14
NZ511825A (en) 2003-08-29
TR200101498T2 (tr) 2001-11-21
AR021400A1 (es) 2002-07-17
RU2001117757A (ru) 2004-02-27
IL143303A0 (en) 2002-04-21
AU764216B2 (en) 2003-08-14
HUP0200749A2 (en) 2002-08-28
JP3432800B2 (ja) 2003-08-04
HK1042084B (zh) 2005-09-02
PL347884A1 (en) 2002-04-22
CN1332731A (zh) 2002-01-23
MY128488A (en) 2007-02-28
HK1042084A1 (en) 2002-08-02
NO20012570D0 (no) 2001-05-25
US6448271B1 (en) 2002-09-10
WO2000032579A1 (de) 2000-06-08
DK1133477T3 (da) 2004-06-21
BG65047B1 (bg) 2007-01-31
CA2352554C (en) 2006-10-10
NO20012570L (no) 2001-07-13
HUP0200749A3 (en) 2003-03-28
CZ300148B6 (cs) 2009-02-25
EP1133477B1 (de) 2004-02-18
KR100417779B1 (ko) 2004-02-05
ZA200104118B (en) 2002-05-21
PT1133477E (pt) 2004-06-30
SK285529B6 (sk) 2007-03-01
UA61158C2 (uk) 2003-11-17
PL196367B1 (pl) 2007-12-31
ATE259789T1 (de) 2004-03-15
DE59908600D1 (de) 2004-03-25
SK7142001A3 (en) 2001-12-03
ES2216625T3 (es) 2004-10-16
IL143303A (en) 2006-12-10

Similar Documents

Publication Publication Date Title
HRP20010484B1 (hr) Supstituirani benzimidazoli, njihovo pripravljanje i korištenje
HRP20020617B1 (en) Substituted oxazolidinones and ther use in the field of blood coagulation
CA2405521A1 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
HRP20110498T1 (hr) Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
CA2474192A1 (en) Nicotinamide derivates useful as p38 inhibitors
CO4770950A1 (es) Composicion antiparasitaria para tratamiento y proteccion de animales de compania
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
YU25593A (sh) Derivati acilaminoindola
HUP9801072A2 (hu) Szubsztituált 6-és 7-amino-tetrahidro-izokinolin-karbonsav-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
KR960029335A (ko) 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온
RU2010124606A (ru) Ингибиторы 17-бета-гидроксистероиддегидрогеназы
PL364639A1 (en) Carbamate compounds for use in preventing or treating anxiety disorders
PT934278E (pt) Bis(acridinocarboxamida) e bis(fenazinocarboxamida) como agentes antitumorais
ES435754A1 (es) Procedimiento para la preparacion de amidas aromaticas de compuestos heterociclicos.
ES454668A1 (es) Procedimiento para la preparacion de nuevas homoftalimidas.
FI831548A0 (fi) 3-amino-6-aryl-1,2,4-triazolo/4,3-b/pyridaziner, deras framstaellning och anvaendning
AR048326A1 (es) Derivados de prolinilo
AR044544A1 (es) Procedimiento para la sintesis de compuestos heterociclicos
CY1109429T1 (el) Καρβαμιδικες ενωσεις για χρηση στην προληψη ή τη θεραπεια του πονου λογω νευροπαθειας
ATE447405T1 (de) Verbesserung der lernfähigkeit und des gedächtnisses und amnesie-behandlung
YU63196A (sh) Postupak za dobijanje dioksoazabicikloheksana
ES2567133T3 (es) Proceso para preparar compuestos de benzoimidazol
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: ABBOTT GMBH, DE

Owner name: ABBOTT GMBH & CO. KG, DE

Owner name: ABBOTT DEUTSCHLAND HOLDING GMBH, DE

PPPP Transfer of rights

Owner name: ABBVIE BAHAMAS LTD., BS

Owner name: ABBVIE DEUTSCHLAND GMBH & CO. KG, DE

Owner name: ABBVIE IRELAND UNLIMITED COMPANY, BM

Owner name: GOLIATH HUNDERTZEHNTE VERMOEGENSVERWALTUNGSGESELLS

ODRP Renewal fee for the maintenance of a patent

Payment date: 20171123

Year of fee payment: 19

PBON Lapse due to non-payment of renewal fee

Effective date: 20181123